Blood Cancer Diagnosis: When to Act Quickly and When There’s Time to Ask Questions
Key Takeaways for Busy Providers:
- Few blood cancer diagnoses require treatment within days, and knowing which ones do helps patients avoid unnecessary panic.
- Pathology and molecular testing often reshape the treatment plan, so an initial diagnosis is rarely the final word.
- PCPs can help patients ask about subtype, additional testing recommendations and treatment options before they commit to a plan.
A patient who has just heard the words “leukemia” or “lymphoma” usually wants to know how fast they need to move before they hear anything else. In most cases, there is more time than it feels like in that moment. Some hematologic malignancies are true emergencies and call for treatment within days. Many others, including certain forms of leukemia, lymphoma, and myelodysplastic syndrome (MDS), allow for a period of careful evaluation before a treatment plan is finalized.
Community physicians who understand this distinction can help patients cancel fewer plans than they think they need to, ask the right questions and enter their first hematology visit with realistic expectations.
Moffitt’s Malignant Hematology Program works alongside referring physicians throughout this process, from the first abnormal result through a finalized treatment plan.
Is This a Medical Emergency, or Is There Time to Think It Through?
Urgency in hematology depends heavily on the specific diagnosis.
Acute leukemias with certain complications and a handful of aggressive lymphomas can progress quickly enough that treatment needs to start within days of diagnosis. Chronic lymphocytic leukemia (CLL) behaves differently. Many patients are diagnosed after a routine blood test and feel entirely well, and a period of observation, sometimes called "watch and wait," is standard of care when blood counts are stable and there is no sign of progression.
Slow-growing forms of non-Hodgkin lymphoma follow a similar pattern. Follicular lymphoma that isn't causing symptoms is often monitored with regular checkups rather than treated immediately, which can spare patients from therapy they don't yet need.
Why Doesn't Treatment Start Right After the Biopsy?
An abnormal bone marrow biopsy or pathology report is only the beginning of the diagnostic process. After the initial biopsy, samples typically go through additional testing, including flow cytometry and molecular and cytogenetic analysis to identify the exact subtype and genetic features of the disease.
This step is critical because the subtype often determines treatment itself. Before starting chemotherapy for acute myeloid leukemia (AML), for example, patients typically undergo genetic and molecular testing that helps determine which regimen fits their specific leukemia. MDS follows a comparable process, where molecular testing for gene mutations is layered onto staging to shape a treatment recommendation suited to that patient's disease.
Pathology review itself can also change the diagnosis. One study found that expert second opinion review resulted in a major diagnostic revision in 17.8% of lymphoma cases in one review period and 16.4% in a later one.
Because subtype and molecular findings can shift the diagnosis, a second opinion before treatment starts isn't a vote of no confidence in the original workup. It's a normal part of getting the full picture and provides patients with the confidence that the plan in front of them accounts for everything currently known about their disease.
What Should Patients Ask Before Starting Treatment?
Patients tend to focus on when treatment will start. A short list of questions can help them focus on wether their plan is complete:
- What is the exact subtype of this diagnosis?
- Is any additional testing still pending?
- What treatment options exist, and how do they compare?
- Is there a reasonable window to get a second opinion before starting?
- Should I stop working or cancel my vacation?
If a patient doesn't know what to ask, you have the opportunity as their physician to guide the conversion toward these important points.
How Can a PCP Help in This Window?
The most useful thing a PCP can offer a patient between an abnormal result and a finalized treatment plan is permission to slow down when it’s clinically appropriate.
"A primary care physician's proactive response to concerning blood test results and symptoms can significantly improve patients' fight against these cancers."
-Dr. Rami Komrokji
Helping patients ask precise questions, understand which parts of their workup are still in progress, and see their full range of options before committing to a plan gives them a sense of control at a moment when very little else feels controllable.
Individualized treatment planning, built around each patient’s molecular profile, is central to how treatment decisions come together for patients with hematologic malignancies.
For patients who could benefit from deeper subtype-specific workup, looping in Moffitt’s malignant hematology team can offer another layer of expertise alongside the care they’re already receiving.
FAQs
Is it safe to wait for pathology and molecular testing before starting treatment?
For many hematologic malignancies, there's time to wait for pathology and molecular results, and potentially get a second opinion before starting treatment. Waiting for complete testing allows the treatment team to match therapy to the specific subtype and genetic features of the disease, leading to a more accurate plan.
How long does the workup typically take?
Timelines vary by diagnosis and by how much additional testing is needed. A hematology team can give patients a specific estimate once their initial results are in.
To refer a patient to Moffitt, use our online form or contact a physician liaison. Online referrals are typically responded to in 24-48 hours.
Medically reviewed by Rami Komrokji, MD, vice chair, Department of Malignant Hematology, Malignant Hematology Program.